Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2014

View Archived Issues

Novel FabI inhibitors with promising activity against staphylococcal infections

Cleave Biosciences initiates phase I trial of CB-5083 in patients with solid tumors

Arisaph Pharmaceuticals initiates phase II study of ARI-3037-MO in hypertriglyceridemia

Uncovering de novo mutations that underscore epileptic encephalopathies

FDA grants Vivolux clearance to conduct phase I/II trial of VLX-1570

Updated phase I results for MSC-2156119J in advanced solid tumors

Deciphera Pharmaceuticals patents novel agents for cancer and other disorders

Novel pyrrolotriazines disclosed by Bristol-Myers Squibb for arrhythmia

Aurigene Discovery Technologies designs new NAmPRTase inhibitors

Takeda Pharmaceutical divulges novel ROR-gamma antagonists

Scientists at Roche synthesize novel autotaxin inhibitors

FDA approves Uceris rectal foam for induction of remission of distal ulcerative colitis

MedImmune in-licenses Shionogi's ACS biologic research program

PET imaging of Abeta plaques using a novel 89Zr-labeled MAb

Striverdi Respimat inhalation spray now available in the U.S.

E-6005 shows efficacy and safety in early clinical studies in patients with atopic dermatitis

Amgen reports topline results from phase III study of adalimumab biosimilar in psoriasis

Teva Pharmaceutical begins rolling NDA for CEP-33237

Ruthigen begins phase I/II trial of RUT-5860

Patient enrollment under way in phase II trial of VPI-2690B in diabetic nephropathy

Nabriva Therapeutics granted FDA QIDP and fast track status for lefamulin

Bristol-Myers Squibb to begin a phase I/II study of BMS-986012 in small cell lung cancer

FDA grants priority review to Lucentis submission for diabetic retinopathy

RedoxTherapies licenses Vernalis' vipadenant for immuno-oncology applications

Regen BioPharma files IND application for autologous dendritic cell therapy for breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...